About Mitochondrial ribosome-associated GTPase 1
Mitochondrial ribosome-associated GTPase 1 (MTG1) is a protein
from Homo sapiens identified by UniProt accession
Q9BT17, 334 residues long.
MolForge cross-references it against 0 known binders and
124 disease associations.
Target properties
| Protein name | Mitochondrial ribosome-associated GTPase 1 |
| UniProt accession | Q9BT17 |
| Gene | MTG1 |
| Organism | Homo sapiens |
| Length | 334 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (124)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.52
- prostate cancer · score 0.09
- Brugada syndrome · score 0.08
- Romano-Ward syndrome · score 0.07
- Arrhythmogenic right ventricular dysplasia · score 0.07
- Familial short QT syndrome · score 0.07
- hypertrophic cardiomyopathy · score 0.07
- familial atrial fibrillation · score 0.07
- Familial progressive cardiac conduction defect · score 0.06
- ventricular fibrillation, paroxysmal familial, type 1 · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BT17-F1 | alphafold | PREDICTED | 87.80 | — |
Amino-acid sequence (334 residues)
MRLTPRALCS AAQAAWRENF PLCGRDVARW FPGHMAKGLK KMQSSLKLVD CIIEVHDARI PLSGRNPLFQ ETLGLKPHLL VLNKMDLADL TEQQKIMQHL EGEGLKNVIF TNCVKDENVK QIIPMVTELI GRSHRYHRKE NLEYCIMVIG VPNVGKSSLI NSLRRQHLRK GKATRVGGEP GITRAVMSKI QVSERPLMFL LDTPGVLAPR IESVETGLKL ALCGTVLDHL VGEETMADYL LYTLNKHQRF GYVQHYGLGS ACDNVERVLK SVAVKLGKTQ KVKVLTGTGN VNIIQPNYPA AARDFLQTFR RGLLGSVMLD LDVLRGHPPA ETLP
Explore Mitochondrial ribosome-associated GTPase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets